Structured evidence table for Chromium Satiety Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Chromium Satiety Randomized Trial | Secondary outcomes include cardiovascular disease risk markers, metabolic risk, metabolic gene profile analysis, dietary data, physical activity, satiety level, quality of life and cost analysis. | 2 | Che Wan Mansor WAN (2025) | Evaluating diabetes-specific meal replacements for glycaemic control in overweight and obese patients with T2DM: a protocol for a randomised controlled trial. |
| Chromium Satiety Randomized Trial | Introduction Uncontrolled type 2 diabetes mellitus (T2DM) causes microvascular and macrovascular issues that hike healthcare costs and threaten global health. | 2 | Che Wan Mansor WAN (2025) | Evaluating diabetes-specific meal replacements for glycaemic control in overweight and obese patients with T2DM: a protocol for a randomised controlled trial. |
| Chromium Satiety Randomized Trial | Previous studies have suggested meal replacement (MR) therapy for T2DM, but there were inconsistencies in the results. | 2 | Che Wan Mansor WAN (2025) | Evaluating diabetes-specific meal replacements for glycaemic control in overweight and obese patients with T2DM: a protocol for a randomised controlled trial. |
Source documents